Cabazitaxel Accord Kesatuan Eropah - Poland - EMA (European Medicines Agency)

cabazitaxel accord

accord healthcare s.l.u. - kabazytaksel - nowotwory gruczołu krokowego, odpornego Łożysko - Środki przeciwnowotworowe - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Abiraterone Accord Kesatuan Eropah - Poland - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Vildagliptin / Metformin hydrochloride Accord Kesatuan Eropah - Poland - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - leki stosowane w cukrzycy - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 dla dostępnych danych o różnych kombinacjach).

Dimethyl fumarate Accord Kesatuan Eropah - Poland - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).